Analyst Price Targets — GLTO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 17, 2026 1:46 pm | — | UBS | $45.00 | $30.50 | TheFly | Galecto initiated with a Buy at UBS |
| February 17, 2026 12:38 pm | — | Guggenheim | $40.00 | $29.12 | TheFly | Galecto price target raised to $40 from $36 at Guggenheim |
| January 7, 2026 12:34 pm | — | Leerink Partners | $46.00 | $21.84 | TheFly | Galecto initiated with an Outperform at Leerink |
| December 8, 2025 1:14 pm | — | Guggenheim | $36.00 | $25.72 | TheFly | Galecto price target raised to $36 from $32 at Guggenheim |
| December 1, 2025 1:07 am | — | Guggenheim | $32.00 | $17.78 | TheFly | Galecto initiated with a Buy at Guggenheim |
| October 17, 2024 7:22 am | Jay Olson | Oppenheimer | $10.00 | $6.71 | StreetInsider | Galecto (GLTO) PT Raised to $10 at Oppenheimer |
Latest News for GLTO
Shares of Galecto, Inc. (NASDAQ: GLTO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and two
Galecto, Inc. (NASDAQ: GLTO - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 13th, there was short interest totaling 277,004 shares, a growth of 86.6% from the January 29th total of 148,474 shares. Approximately 19.4% of the company's stock are short sold. Based
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the closing of its previously announced underwritten public offering of 16,644,737 shares of its common stock, including the full exercise of the underwriters' option to purchase up to…
BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the pricing of its previously announced underwritten public offering of shares of its common stock. Galecto is selling a total of 14,473,685 shares of common stock at a public offering…
Shares of Galecto, Inc. (NASDAQ: GLTO - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five ratings firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GLTO.
U.S. House Trading
No House trades found for GLTO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.